Details of the Drug

General Information of Drug (ID: DMGQF3R)

• Drug Name: Remoxipride
• Synonyms: Remoxiprida; Remoxipridum; Romoxipride; A 33547; FLA 731; A-33547; FLA-731; Remoxiprida [INN-Spanish]; Remoxipride (USAN); Remoxipridum [INN-Latin]; Remoxipride [USAN:BAN:INN]; (-)-(S)-3-Brom-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamid; (-)-(S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; (-)-n-ethyl-2-(3-bromo-2,6-dimethoxybenzamidomethyl)pyrrolidine; (S)-3-Bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; (S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Withdrawn from market	[1]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 371.27
  Logarithm of the Partition Coefficient (xlogp); 2.1
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 39 +/- 9 micromolh/L [2]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 5.5 +/- 1.1 micromol/L [2]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.8 +/- 0.2 h [2]
  Bioavailability: The bioavailability of drug is 90% [2]
  Clearance: The renal clearance of drug is 23.6 +/- 7.0 mL/min [2]
  Elimination: 89% of drug is recovered in the urine and 7% of drug is recovered in the feces [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5.1 +/- 1.6 hours (in patients with normal creatinine clearance), 6.1 +/- 2.6 hours (in patients with moderate renal impairment), and 9.9 +/- 3.8 hours (in patients with severe renal impairment) [2]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.16% [4]
  Vd: The volume of distribution (Vd) of drug is 44.3 +/- 8.3 L [2]
• Chemical Identifiers:
  Formula: C16H23BrN2O3
  IUPAC Name: 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
  Canonical SMILES: CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC
  InChI: InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
  InChIKey: GUJRSXAPGDDABA-NSHDSACASA-N
• Cross-matching ID:
  PubChem CID: 54477
  ChEBI ID: CHEBI:92948
  CAS Number: 80125-14-0
  DrugBank ID: DB00409
  TTD ID: D01PIL
  INTEDE ID: DR1403

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Schizophrenia
• ICD Disease Classification: 6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01

References

• [1] Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist. CNS Drug Rev. 2001 Fall;7(3):265-82.
• [2] The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. Br J Clin Pharmacol. 1993 Jun;35(6):615-22. doi: 10.1111/j.1365-2125.1993.tb04191.x.
• [3] von Bahr C, Movin G, Yisak WA, Jostell KG, Widman M: Clinical pharmacokinetics of remoxipride. Acta Psychiatr Scand Suppl. 1990;358:41-4. doi: 10.1111/j.1600-0447.1990.tb05284.x.
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
• [6] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.